Literature DB >> 29800675

Intra-accumbal administration of AMN082, a metabotropic glutamate receptor type 7 allosteric agonist, inhibits the acquisition but not the expression of morphine-induced conditioned place preference in rats.

Mahsaneh Vatankhah1, Saeideh Karimi-Haghighi2, Abdolrahman Sarihi1, Abbas Haghparast3.   

Abstract

The nucleus accumbens (NAc) plays a primary role in opioid reward. The actions of glutamate are mediated by the activation of ionotropic and metabotropic glutamate receptors (mGluRs). Previous documents have shown the extensive distributions of the different types of mGluRs, including mGluR7, in regions that are involved in opioid reward, such as the NAc. In this study, seventy male Wistar rats were used to investigate the role of mGluR7 receptors in the NAc on the acquisition and expression of morphine-induced conditioned place preference (CPP). In Experiment 1, to determine the effect of AMN082, a selective mGluR7 allosteric agonist, on the acquisition of morphine-induced conditioned place preference (CPP), the rats bilaterally received AMN082 (1, 3 and 5 μg/0.5 μL DMSO) during three-day conditioning by morphine (5 mg/kg). In Experiment 2, the rats bilaterally received AMN082 (5 μg/0.5 μL DMSO) 5 min prior to the post-conditioning test to investigate the effect of AMN082 on the expression of morphine-induced CPP. The results showed that the intra-accumbal injection of AMN082 prevents the acquisition of morphine-induced CPP in a dose-dependent manner. However, intra-accumbal injection of AMN082 had no effect on the expression of morphine-induced CPP. The findings propose that the mGluR7 in the NAc inhibits the acquisition of morphine-induced CPP that could be mediated by inhibition of NMDA receptors in the NAc.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acquisition; Expression; Metabotropic glutamate receptor type 7 (mGluR7); Morphine; Nucleus accumbens; Reward

Mesh:

Substances:

Year:  2018        PMID: 29800675     DOI: 10.1016/j.neulet.2018.05.031

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  Neuroinflammatory Response in Reward-Associated Psychostimulants and Opioids: A Review.

Authors:  Saeideh Karimi-Haghighi; Sara Chavoshinezhad; Roghayeh Mozafari; Farshid Noorbakhsh; Afshin Borhani-Haghighi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2022-04-23       Impact factor: 5.046

2.  Compensatory Role of Insulin in the Extinction but Not Reinstatement of Morphine-Induced Conditioned Place Preference in the Streptozotocin-Induced Diabetic Rats.

Authors:  Atieh Chizari; Rezvan Hassanpour; Saeideh Karimi-Haghighi; Ronak Azizbeigi; Somaye Mesgar; Zahra Mousavi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2022-02-21       Impact factor: 3.996

Review 3.  Cannabidiol and substance use disorder: Dream or reality.

Authors:  Saeideh Karimi-Haghighi; Yasaman Razavi; Daniela Iezzi; Andrew F Scheyer; Olivier Manzoni; Abbas Haghparast
Journal:  Neuropharmacology       Date:  2022-01-13       Impact factor: 5.273

4.  Cocaine-Induced Sensitization is Linked to Distal Chromosome 6 Region in Congenic Mouse Model.

Authors:  Csaba Vadasz; Beatrix M Gyetvai
Journal:  Drug Alcohol Depend       Date:  2020-07-23       Impact factor: 4.492

5.  The role of mGlu4 receptors within the nucleus accumbens in acquisition and expression of morphine-induced conditioned place preference in male rats.

Authors:  Zahra Ebrahimi; Nazanin Kahvandi; Alireza Komaki; Seyed Asaad Karimi; Marzieh Naderishahab; Abdolrahman Sarihi
Journal:  BMC Neurosci       Date:  2021-03-21       Impact factor: 3.288

6.  The effect of the mGlu8 receptor agonist, (S)-3,4-DCPG on acquisition and expression of morphine-induced conditioned place preference in male rats.

Authors:  Nazanin Kahvandi; Zahra Ebrahimi; Seyed Asaad Karimi; Siamak Shahidi; Iraj Salehi; Marzieh Naderishahab; Abdolrahman Sarihi
Journal:  Behav Brain Funct       Date:  2021-02-21       Impact factor: 3.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.